LOGIN  |  REGISTER
C4 Therapeutics
Chimerix

Sensus Healthcare to Present at The Microcap Conference 2025

January 23, 2025 | Last Trade: US$4.48 0.02 0.45

BOCA RATON, Fla. / Jan 23, 2025 / Business Wire / Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.

Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company’s recent developments, growth strategy, and investment opportunities.

Event: The Microcap Conference 2025
Location: Studio 2, Borgata Hotel Casino & Spa
Date: Thursday, January 30, 2025
Time: 2:00 PM Eastern Time

Investors interested in meeting with management can register for the conference here.

About Sensus Healthcare

Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

Recursion

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page